☆ 4.6 Article

A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

Related references

Note: Only part of the references are listed.

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Genetics & Heredity

EFNA3 Is a Prognostic Biomarker Correlated With Immune Cell Infiltration and Immune Checkpoints in Gastric Cancer

Peng Zheng et al.

Summary: EFNA3 expression in gastric cancer is associated with prognosis and immune infiltration, and can be used as a prognostic and immune infiltration and checkpoint marker in gastric cancer patients.

FRONTIERS IN GENETICS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma

Abdullah Husain et al.

Summary: In hepatocellular carcinoma (HCC), the Ephrin-A3/EphA2 axis plays a significant role as a hypoxia-sensitive modulator of HCC cell metabolism and a key contributor to HCC initiation and progression.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The EPH/Ephrin System in Colorectal Cancer

Stavros P. Papadakos et al.

Summary: The EPH/ephrin system is a bidirectional signaling pathway that plays an important role in carcinogenesis. Despite advancements in the diagnosis and treatment of CRC, it remains a leading cause of global death. Recent research has provided new insights into the role of EPH/ephrins in the pathogenesis and treatment of CRC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Oncology

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review

Matthias Pinter et al.

Summary: Recent advancements in the treatment of advanced hepatocellular carcinoma (HCC) have led to the approval of new systemic therapies such as angiogenesis inhibitors and immune checkpoint blockers, indicating important progress in the field. Strategies to target immunosuppression in tumors, such as vascular endothelial growth factor pathway inhibition and transforming growth factor-beta pathway inhibition, show promise in enhancing the efficacy of immunotherapy in HCC. Successes and failures of these treatments have provided insights into implementing novel systemic therapy in HCC and improving immunotherapy efficacy for this disease.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma

Mingming Deng et al.

Summary: In this study, we found that increased EFNA3 expression in LUAD patients predicted worse clinical prognosis, promoted LUAD cell proliferation and glycolysis ability, and was related to immunotherapy response. Mechanistically, EFNA3 may be involved in pathways related to nuclear division, synaptic function, and ion channel activity. Furthermore, EFNA3 was negatively correlated with immunity, stromal infiltration, and various tumor infiltrating immune cells (TIICs), but positively associated with multiple immunotherapy biomarkers.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Review Oncology

Systemic therapy of advanced hepatocellular carcinoma

Peter R Galle et al.

Summary: For a decade, sorafenib was the main treatment for advanced hepatocellular carcinoma, but recent approvals of new systemic treatments, including immunotherapies, have shifted the landscape. The combination of a checkpoint inhibitor with a VEGF antibody has shown promising results, raising questions about treatment choices and sequences.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

D. J. McGrail et al.

Summary: Analysis of over 10,000 patient tumors from The Cancer Genome Atlas showed that TMB-H tumors had significantly higher response rates to immune checkpoint blockade in certain cancer types, while showing no significant benefit in others. These results do not support the use of TMB-H as a biomarker for ICB treatment across all solid cancer types, indicating the need for further tumor type-specific studies.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors

Csongor Gyoergy Lengyel

Summary: This article discusses the immunotherapy treatment of microsatellite instable colorectal cancer, highlighting the correlation between increased tumor-specific neoantigens in hypermutated tumors with immune cells and immune checkpoint receptors, as well as the importance of neoantigen recognition in immunotherapy.

CURRENT DRUG TARGETS (2021)

Add to Collection

Article Oncology

Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT

Yao Zhao et al.

Summary: The study revealed that Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT, suggesting it may be a potential therapeutic target in metastatic prostate cancer.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin et al.

Summary: The study demonstrates that atezolizumab plus bevacizumab significantly improves overall survival and progression-free survival in Chinese patients with unresectable hepatocellular carcinoma compared to sorafenib, with hypertension being the most common grade 3-4 adverse event and other high-grade adverse events being infrequent.

LIVER CANCER (2021)

Add to Collection

Article Medicine, Research & Experimental

EFNA4 promotes cell proliferation and tumor metastasis in hepatocellular carcinoma through a PIK3R2/GSK3β/β-catenin positive feedback loop

Junhao Lin et al.

Summary: EFNA4 plays a crucial role in promoting proliferation and migration of HCC cells, and its overexpression is associated with poor prognosis. EFNA4 regulates the PIK3R2/GSK3 beta/beta-catenin loop to influence the survival and migration of HCC cells.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

Add to Collection

Review Oncology

Eph Receptors in the Immunosuppressive Tumor Microenvironment

Peter W. Janes et al.

Summary: Eph receptors and their ligands play critical roles in the tumor microenvironment, and inhibiting their functions can enhance the efficacy of immune-based therapies.

CANCER RESEARCH (2021)

Add to Collection

Article Cell Biology

MiR-210-3p-EphrinA3-PI3K/AKT axis regulates the progression of oral cancer

Lin Wang et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

Add to Collection

Article Oncology

Ephrin-B1 Is a Novel Biomarker of Bladder Cancer Aggressiveness. Studies in Murine Models and in Human Samples

Maria Victoria Mencucci et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors

Ignacio Garrido-Laguna et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

A. B. Schrock et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Ju Dong Yang et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Review Oncology

Correlations between microsatellite instability and the biological behaviour of tumours

Guang Yang et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Roles of EphA1/A2 and ephrin-A1 in cancer

Katsuaki Ieguchi et al.

CANCER SCIENCE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiology and Management of Hepatocellular Carcinoma

Laura Kulik et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Genetics & Heredity

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert M. Samstein et al.

NATURE GENETICS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Jianfang Liu et al.

CELL (2018)

Add to Collection

Article Immunology

The Immune Landscape of Cancer

Vesteinn Thorsson et al.

IMMUNITY (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

GeneMANIA update 2018

Max Franz et al.

NUCLEIC ACIDS RESEARCH (2018)

Add to Collection

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

Add to Collection

Article Oncology

Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1

Kazunori Iwasaki et al.

CANCER SCIENCE (2018)

Add to Collection

Review Chemistry, Medicinal

Targeting Eph/ephrin system in cancer therapy

Alessio Lodola et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)

Add to Collection

Letter Biotechnology & Applied Microbiology

Toil enables reproducible, open source, big biomedical data analyses

John Vivian et al.

NATURE BIOTECHNOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Ephrin B1-mediated repulsion and signaling control germinal center T cell territoriality and function

Peiwen Lu et al.

SCIENCE (2017)

Add to Collection

Article Multidisciplinary Sciences

A molecular portrait of microsatellite instability across multiple cancers

Isidro Cortes-Ciriano et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study

Christina Fitzmaurice et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Classification and characterization of microsatellite instability across 18 cancer types

Ronald J. Hanse et al.

NATURE MEDICINE (2016)

Add to Collection

Article Neurosciences

The Ephrin-A5/EphA4 Interaction Modulates Neurogenesis and Angiogenesis by the p-Akt and p-ERK Pathways in a Mouse Model of TLE

Yi Shu et al.

MOLECULAR NEUROBIOLOGY (2016)

Add to Collection

Article Oncology

Anti-EFNA4 Calichearnicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

Marc Damelin et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Oncology

Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma

Hiroshi Wada et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels

Paul Geeleher et al.

PLOS ONE (2014)

Add to Collection

Article Multidisciplinary Sciences

A Novel Role for Adipose Ephrin-B1 in Inflammatory Response

Takuya Mori et al.

PLOS ONE (2013)

Add to Collection

Article Oncology

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Douglas Hanahan et al.

CANCER CELL (2012)

Add to Collection

Review Cell Biology

The multifaceted roles of Eph/ephrin signaling in breast cancer

Philip Kaenel et al.

CELL ADHESION & MIGRATION (2012)

Add to Collection

Article Immunology

The effect of conditional EFNB1 deletion in the T cell compartment on T cell development and function

Wei Jin et al.

BMC IMMUNOLOGY (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Efnb1 and Efnb2 Proteins Regulate Thymocyte Development Peripheral T Cell Differentiation, and Antiviral Immune Responses and Are Essential for Interleukin-6 (IL-6) Signaling

Hongyu Luo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Add to Collection

Review Oncology

Ephrin expression and function in cancer

Jennifer K. McCarron et al.

FUTURE ONCOLOGY (2010)

Add to Collection

Article Gastroenterology & Hepatology

Liver Cancer: EphrinA2 Promotes Tumorigenicity Through Rac1/Akt/NF-κB Signaling Pathway

Yu-Xiong Feng et al.

HEPATOLOGY (2010)

Add to Collection

Review Biochemistry & Molecular Biology

Eph-ephrin bidirectional signaling in physiology and disease

Elena B. Pasquale

CELL (2008)

Add to Collection

Article Biochemistry & Molecular Biology

Ephrin-B1 is critical in T-cell development

G Yu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Add to Collection

Review Oncology

Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression

M Héroult et al.

EXPERIMENTAL CELL RESEARCH (2006)

Add to Collection

Article Biochemistry & Molecular Biology

EphrinB1 is essential in T-cell-T-cell co-operation during T-cell activation

G Yu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2004)

Add to Collection

Review Biochemistry & Molecular Biology

The role of ephrins and Eph receptors in cancer

H Surawska et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2004)

Add to Collection

Review Cell Biology

Mechanisms and functions of EPH and ephrin signalling

K Kullander et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.